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Aim of the project  
 
The aim of his project is to investigate the pathogenic mechanisms underlying 
Parkinson's disease (PD), the second most common neurodegenerative disorder 
after Alzheimer's disease, and to develop and validate an alternative therapeutic 
approach to common treatments using plant extracts in preventive and/or 
medicative roles against the progression of Parkinson's disease. 
Specifically, this research intends to gain more knowledge on some aspects of the 
disease in a powerful PD genetic model, Drosophila melanogaster (Dm), a 
relatively simple organism that shares many basic biological, physiological and 
neurological features with vertebrates, including humans. Nearly 75% of human 
disease-causing genes have a functional homolog in the fly, the manipulation of 
which allows the creation of excellent experimental models. 
Two types of transgenic mutants of  Drosophila melanogaster, expressing human 
variants of Parkinson's disease, have been used in this project: loss-of-function 
PINK1
B9
 (with a deletion of 570 bp in PINK1 Kinase domain) and loss-of-function 
LRRK2
WD40 
(with a deletion of 464 bp in LRRK WD40 domain). The validity of 
the PINK1
B9
 model derives from many lines of research [1,2], while LRRK2
WD40
 is 
a variant of LRRK2 mutation still scantily studied (previously named LRRK
ex1
; 
[3]).  
Mutations in the human gene PINK1 are traditionally associated with familial 
forms of early-onset PD. The encoded protein acts as a mitochondrial kinase and is 
involved in many biological processes, often in response to oxidative stress. 
Mutations in the LRRK2 human gene are linked to the autosomal dominant 
inheritance type of PD. The protein expressed is involved in neurogenesis, 
endocytosis/vesicles trafficking and autophagy system as well as in other 
mechanisms. The specific phenotypic differences open the way to potential 
specific pharmacological treatments, even with a neuroprotective type mode. 
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The aim of the project is also to test the efficacy of plant species Mucuna pruriens 
(Mpe) and Withania somnifera (Wse) - used for centuries in Ayurveda medical 
therapy - in preventing or delaying the degeneration of dopaminergic neurons and 
motor/non-motor deficits in Drosophila mutants. 
The parameters considered for the experimental design are lifespan, motor activity, 
olfactory response, synaptic protein expression, mitochondria and synaptic active 
zone morphology, both in treated and untreated flies. 
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Introduction 
       
Parkinson's disease 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder 
after Alzheimer’s disease, affecting more than 1% of the population over age 60, 
with an increased incidence closely correlated with aging. PD is characterized by 
the selective degeneration of dopaminergic (DA) neurons in the substantia nigra 
pars compacta and, in many cases, by the accumulation of cytoplasmic aggregates 
of eosinophilic proteins (Lewy bodies), including α-synuclein, ubiquitin and 
parkin, in brain stem, spinal cord, and cortical regions [4–6]. A precise diagnosis 
that identifies a specific type of the disease is still extremely difficult, also due to 
the lack of diagnostic tests [7]. Parkinson’s disease belongs to a wide spectrum of 
diseases named “parkinsonisms" that share common symptoms and causes - such 
as striatal DA deficiency or striatal damage - of which PD represents ∼80% of 
cases [8].  
Parkinson’s disease presents with motor defects, such as resting tremor, akinesia, 
postural instability and muscle rigidity, and with non-motor defects, such as 
neuropsychiatric, autonomic, gastrointestinal and sensory symptoms, but the onset 
is gradual and the earliest symptoms might be unidentified by clinicians and not 
readily related to the syndrome. Events from depression, anxiety, fibromyalgia to 
shoulder pain, commonly occur about 4-6 years before the onset of typical severe 
symptoms, as well as olfactory dysfunctions, constipation and sleep behavior 
disorders which might precede the manifestation of motor deficits by 10 years [9–
11]. The impairment of locomotor function appears when at least 50% of nigral 
DA neurons and 70% of putaminal DA have been lost and the degeneration is 
complete by about 4-5 years post-diagnosis [6,12].  
Unfortunately, therapeutic treatments to limit the onset of PD are not yet available: 
up to now the common approach to treating patients is to intervene by relieving 
symptoms. To this end, the drug most commonly used for symptomatic therapy is 
levodopa (l-3,4-dihydroxyphenylalanine; l-dopa), the physiological amino acid 
precursor of dopamine [13]. For many years the positive effects of the 
11 
 
administration of levodopa in Parkinson patients have been known: they include 
alleviating some of the locomotor complications, but the side effects of high doses 
and long-term treatment, such as dyskinesia, postural hypotension and motor 
fluctuation  have also been discovered [11,12 review]. Moreover, a review by 
Chaudhuri and Schapira [11], suggests that treatment with levodopa might also be 
used to counteract non-motor symptoms, but it is necessary to point out that in 
some cases the therapy may produce the opposite result, causing a worsening of the 
events. The action mechanism of levodopa in counteracting Parkinson’s disease 
remains uncertain and a valid therapy without side effects in preventing motor and 
non-motor symptoms is not currently available. 
 
 
Genes Associated with Parkinson's disease 
At present, the pathogenesis of Parkinson’s disease has still not been completely 
defined, but it is clear that the etiology of the disorder is multifactorial, i.e. a 
complex interaction between genetic and environmental factors [4]. About 90% of 
PD cases are sporadic but, in the remaining cases, the disease is inherited in 
autosomal recessive or dominant modality [8].  
Several loci have been identified for monogenic forms of PD, but there are five 
clearly defined genes for which a single mutation is sufficient to cause the 
phenotype: LRRK2 (PARK8), SNCA (PARK1), PINK1(PARK6), Parkin 
(PARK2), DJ-1(PARK7).  
Hundreds of distinct genetic variants of these five genes have been reported in 
Mendelian (familial) forms of disease. Mutations in SNCA and LRRK2 genes are 
associated with a dominant form of the disease, while mutations in PINK1, Parkin 
and DJ-1 cause recessive early onset parkinsonism (age of onset <40 years) [16].  
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Drosophila melanogaster as a PD model 
Research on PD in human subjects is limited by technical and ethical issues. 
Cellular models commonly used for molecular, biochemical, and pharmacological 
approaches are not completely reliable. For this reason it has been necessary to 
develop a genetic modeling system to allow the in vivo study of functional 
processes related to the pathology to confirm data obtained on cell lines. Among 
the animal models used in the study of neurodegenerative disorders, a valuable 
system for basic studies of neuronal development, activity and dysfunction is the 
fruit fly Drosophila melanogaster (Dm). The fruit fly is considered a valuable 
model for studying several complex biological processes [17–19] owing to several 
features, such as ease of maintenance, rapid reproductive cycle and short lifespan 
and a complex behavior driven by a sophisticated nervous system. It is of particular 
interest to underline that the Dm nervous circuit is composed of ~100,000 neurons 
and, recalling that the most characteristic symptom of PD is the progressive loss of 
dopaminergic neurons, 200 neurons are led by the neurotransmitter DA. Moreover, 
the genome of Dm has been completely encoded and most of the human genes, 
including those involved in PD, are evolutionarily conserved in the fly [19]. Dm 
gene expression is easily manipulable with several techniques and tools, therefore 
their loss-of-function (LOF) or gain-of-function (GOF) can be analyzed and genetic 
and pharmacological modulation of the phenotypes can be evaluated [20]. Besides, 
most of the genes implicated in familial forms of the disease have at least one fly 
homolog [21]. This work focuses on PINK1
 
and LRRK2 Drosophila melanogaster 
homolog genes. 
 
 
PINK1 Domain Structure and Mutations  
The PINK1 gene (phosphatase and tensin homolog (PTEN)-induced putative 
kinase 1; PARK6) that encodes the homonymous serine/threonine kinases protein 
consists of eight exons, 581 amino acid and shows two domain structures: a 
mitochondrial targeting motif and a kinase domain. In human the transcript is 
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ubiquitously expressed but, in the brain, the higher expression is localized in 
substantia nigra, hippocampus neurons and cerebellar Purkinji cells [22–24]. 
PINK1 protein is involved in synaptic vesicular transport system and in the 
response to mitochondrial oxidative stress [24,25], but its role is not yet completely 
clear. Moreover, several studies in flies and vertebrates highlight its closely link to 
Parkin protein activity (parkin RBR E3 ubiquitin protein ligase protein, encoded by 
the PARK2-Parkin gene), showing how the PINK1/Parkin pathway play a role in 
mitochondrial dynamics and morphology [16,23,26–28]. Different types of 
mutations (nonsense, missense, small insertions and deletions, and whole-gene or 
single/multiple exon variations mutations), distributed along the entire gene within 
and outside the kinase domain, are the most common cause of recessive familial  
Parkinsonism [23,24]. Drosophila melanogaster contains a single PINK1 
homologue which shares with human PINK1 43% amino acid identity and 60% 
similarity [26,29]. 
 
 
LRRK2 Domain Structure and Mutations 
The LRRK2 gene consists of a genomic region of 51 exons and is characterized by 
the presence several independent domains: Roc (Ras GTPase family), COR (C-
terminal of Roc), Kinasi (serine/theronine and tyrosine kinase family) and protein-
protein interaction domains LRR (leucine rich repeats) and C-terminal WD40 
domain [30,31].  LRKK2 gene coding for an unusually large protein composed of 
2527 amino acids is widely expressed in the brain and other organs; several studies 
have detected the presence of the protein in specific brain regions such as cortex, 
striatum, hippocampus, cerebellum and in the dopaminergic neurons of the 
substantia nigra [32–35]. The LRRK2 roles, listed in the Berwick and Harvey 
review [31], include neurogenesis and neurite outgrowth, cytoskeleton assembly, 
endocytosis/vesicles trafficking and autophagy coordination. LRRK2 mutations are 
the most common cause of both familial and sporadic forms of late onset PD 
worldwide. Li et al. [33, review] summarized the possible involvement of 
mutations of the LRRK2 gene in many pathogenic mechanisms of PD such as 
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inflammatory response, oxidative stress, mitochondrial dysfunction, synaptic 
dysfunction and lysosomal system disorder. Drosophila melanogster has a sole 
homologue of human LRRK2 which shares similar GTPase and kinase domains, 
with 46% and 44% homology respectively [37]. 
 
 
Mucuna pruriens 
Mucuna pruriens, also known as velvet bean, is a perennial semi-woody climberis 
that belongs to the family of Fabaceae, endemic in India and other tropical 
countries. The extract of Mucuna pruriens (Mpe) is a popular Indian medicinal 
plant, which has long been used in traditional Indian Ayurvedic medicine for a 
variety of purposes, such as carminative, hypertensive and hypoglycemic agent. It 
is also used as an aphrodisiac, diuretic, vermifuge and used for cancer, cholera, 
asthma, pleuritis, cough, dog- and snakebite, etc. [38–40]. Mucuna seed 
composition shows several compounds: proteins, lipids, carbohydrates and 
numerous minerals as well as a series of active ingredients such a alkaloids, 
glutathione, nicotine and serotonin. Moreover, Mpe has been suggested to be useful 
against Parkinson's symptoms considering that the endocarps contain a 
fundamental amino acid compound, levodopa (L-3,4- dihydroxyphenylalanine, L-
Dopa), a main precursor of the neurotransmitter dopamine, in 4-10% w/w amounts 
[39,41,42]. In this respect, some clinical studies have evaluated the therapeutic 
efficacy of Mpe as a natural alternative to commonly used (levodopa) anti-
Parkinsonian drugs in humans [43–45]. Mpe provides alleviation of parkinsonism 
as well as levodopa treatment and has been reported not to cause drug-induced 
dyskinesia [43]. However, it may cause other side effects, such as gastrointestinal 
dysfunction due to absorption of oral treatments, as in the Lieu et al. [42] test on 
parkinsonian primates. It is assumed that the therapeutic activity of Mucuna 
pruriens may not be attributed to the L-dopa content of the plant alone, but may be 
due to the synergic action of one or more active components and secondary 
metabolites [40,44,46].  
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Withania somnifera 
Withania somnifera,  also known as Ashwagandha or Indian ginseng, is a perennial 
shrub that belongs to the family of Solanaceae, widely distributed in Africa, 
Southern Europe and Asia, but also geographically identified in the Italian islands - 
Sardinia and Sicily [47,48]. The plant is commonly used as a herbal drug in 
traditional Indian Ayurveda medicine for over 3000 years, owing to its several 
beneficial effects, including anti-oxidant, anti-inflammatory, anti-tumor and 
immunomodulatory activity [47,49,50]. The biochemical composition of  W. 
somnifera root is complex, several biologically active chemicals are known: they 
include  alkaloids (ashwagandhine, cuscohygrine, anahygrine, tropine etc.) and 
steroidal lactone (a class of constituents known as withanolides such as withaferin 
A, withanone, withanolide WS-1, Withanolide A-Y, withasomniferina-A, 
withasomidienone, withasomniferoli) [49,51]. These phytochemical constituents 
present in Withania somnifera are reported to counteract the excitotoxicity, 
oxidative damage and promote neuroprotective activity [52,53]. Therefore, the 
traditional uses and several studies suggest that Wse may possibly be useful also in 
treating, among others illnesses, neurodegenerative diseases [50,52,54]. Studies 
have revealed that Wse may be helpful in protecting against neuronal injury in 
Parkinson's disease in murine models [50,55,56].  
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Abstract 
 
The fruit fly Drosophila melanogaster (Dm) mutant for PTEN-induced putative 
kinase 1 (PINK1
B9
) gene is a powerful tool to investigate physiopathology of 
Parkinson's disease (PD). Using PINK1
B9
 mutant Dm we sought to explore the 
effects of Mucuna pruriens methanolic extract (Mpe), a L-Dopa-containing herbal 
remedy of PD. The effects of Mpe on PINK1
B9
 mutants, supplied with standard 
diet to larvae and adults, were assayed on 3–6 (I), 10–15 (II) and 20–25 (III) days 
old flies. Mpe 0.1% significantly extended lifespan of PINK1
B9
 and fully rescued 
olfactory response to 1-hexanol and improved climbing behavior of PINK1
B9
 of all 
ages; in contrast, L-Dopa (0.01%, percentage at which it is present in Mpe 0.1%) 
ameliorated climbing of only PINK1
B9
 flies of age step II. Transmission electron 
microscopy analysis of antennal lobes and thoracic ganglia of PINK1
B9
 revealed 
that Mpe restored to wild type (WT) levels both T-bars and damaged mitochondria. 
Western blot analysis of whole brain showed that Mpe, but not L-Dopa on its own, 
restored bruchpilot (BRP) and tyrosine hydroxylase (TH) expression to age-
matched WT control levels. These results highlight multiple sites of action of Mpe, 
suggesting that its effects cannot only depend upon its L-Dopa content and support 
the clinical observation of Mpe as an effective medication with intrinsic ability of 
delaying the onset of chronic L-Dopa-induced long-term motor complications. 
Overall, this study strengthens the relevance of using PINK1
B9
 Dm as a 
translational model to study the properties of Mucuna pruriens for PD treatment. 
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Introduction 
Several reports on antiparkinsonian activity of Mucuna pruriens (Mp) [13] [14] 
endorse the use of Mp seeds in PD. In addition to L-Dopa, Mp seeds contain 
genistein and polyunsaturated fatty acids which support its Parkinson’s disease 
(PD) is, after the Alzheimer’s disease, the second most prevalent 
neurodegenerative disease first affecting medulla oblongata, olfactory bulb and 
substantia nigra [1]. Loss of olfaction is a very consistent marker of PD occurring 
in 95% of patients early before the onset of motor symptoms [2]. Olfactory 
dysfunction is observed in PTEN-induced putative kinase 1 (PINK1
B9
) 
Parkinsonism, both in humans [3] and in animal models of PD [4]. The Drosophila 
melanogaster (Dm) PINK1
B9
 mutant model recapitulates several of the essential 
features of PD [5] and has been used to study neuronal dysfunction and molecular 
aspects of neurodegeneration [6]. In particular, PINK1
B9
 model provides major 
information regarding pathogenic molecular basis of early onset PD and 
mitochondrial dysfunction [5]. Accordingly, it was recently reported that PINK1 
mutation enhances mitochondrial stress-induced neurodegeneration in mice [7]. 
L-Dopa is the most effective symptomatic medication of PD and is still considered 
the gold standard in its treatment, although other drugs such as dopamine (DA) 
agonists, DA uptake and mono amino oxidase-B inhibitors are commonly used in 
the clinical management of PD patients [8] [9] [10]. Besides, other drugs such as 
adenosine A2A antagonists used as adjunct might be effective in the symptomatic 
treatment of PD [11]. In addition, the involvement of non-dopaminergic 
neurotransmitters such as noradrenaline, serotonin, glutamate, and acetylcholine in 
different brain areas like cortex, brainstem and basal ganglia has prompted many 
researchers to investigate the effects of non-dopaminergic drugs [12] indicating the 
involvement of multiple targets in treatment of PD. Several reports on 
antiparkinsonian activity of Mucuna pruriens (Mp) [13] [14] endorse the use of Mp 
seeds in PD. In addition to L-Dopa, Mp seeds contain genistein and 
polyunsaturated fatty acids which support its antiparkinsonian and neuroprotective 
actions [15]. 
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Furthermore, phytic acid, another Mp constituent with antioxidant and iron 
sequestrant activity, has been reported to suppress methyl-phenyl-
tetrahydropyridine (MPTP) induced hydroxyl radical generation [16]. Hence, in 
view of multiple phytoconstituents supporting antiparkinsonian activity of Mp, the 
present study was aimed at verifying if Mpe’s ability to ameliorate symptoms in 
this PD model might be attributable to L-Dopa only or to the Mp extract as a whole 
in which L-Dopa is present along with other ingredients.  
On these bases we evaluated the antiparkinsonian profile of the standardized 
methanolic extract of the seeds of Mp (Mpe) on lifespan, climbing activity and 
olfactory function in PINK1
B9
 as compared to either wild type (WT) and untreated 
PINK1
B9
 Dm. In addition, in order to gain mechanistic insights on the 
neuroprotective and neuro-rescue properties of Mpe, we also evaluated the 
expression of bruchpilot protein and tyrosine hydroxylase, as well as the 
morphology of presynaptic active zones and mitochondria in flies’antennal lobes, 
i.e. the olfactory bulbs-equivalent structure, and thoracic ganglia, of both WT as 
well as untreated and Mpe-treated PINK1
B9
 mutants. 
Materials and Methods 
Fly Strains 
For these experiments we used adult wild type (WT) Oregon-R (Oregon-R-C) and 
PTEN-induced putative kinase 1 PINK1
B9
 (w[*] Pink1[B9]) mutant Drosophila 
melanogaster (Dm) males (from Bloomington Stock Center; Fly Base: 
http://flybase.bio.indiana.edu). After emergence from pupae, male WT and 
PINK1
B9
 mutant flies were separated. WT and mutant flies were reared on a 
standard cornmeal-yeast-agar medium in controlled environmental conditions (24–
25°C; 60% relative humidity; light/dark = 12/12 hours). In detail, four groups of 
mutant flies were reared on a standard medium supplemented with Mucuna 
pruriens methanolic extract (Mpe) (Batch no. FMPEX/2012060001; Natural 
Remedies Ltd., Bangalore, India). PINK1
B9
 mutants were supplied with Mpe at 
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different concentrations (0 (i.e. untreated PINK1
B9
 mutants), 0.1, 1 and 10% w/w 
in their standard diet) both as larvae and adults (L
+
/A
+
). In addition, another group 
was reared on a standard medium supplemented with 0.01% (0.5 mM) L-Dopa 
(Sigma Aldrich, Milan, Italy), a percentage similar to that at which L-Dopa was 
supplemented with 0.1% Mpe [15]. The effects of Mpe were assayed at different 
age steps (I: 3–6; II: 10–15; III: 20–25 days old). A series of experiments on life 
span, using various concentrations of Mpe (see below in Survival curves) provided 
the basis for selecting the optimal concentration at which conduct the behavioral, 
morphological, and protein expression assessments. In particular, based on lifespan 
results, the olfaction behavior assessments, transmission electron microscopy 
(TEM) and western blot analyses were restricted to group II flies after 0.1% Mpe 
administration as L
+
/A
+
. Standard genetic procedures were used during the study. 
 
Survival curves 
With the aim of selecting the optimal Mpe’s concentration, Dm were grown on 
standard diet supplemented with different concentrations of Mpe at 25°C. Cohorts 
of 40 flies (4 flies/tube) from each experimental group (i.e. WT, untreated and 
Mpe-treated PINK1
B9
) were monitored every 2 days for their survival. Mortality 
was analyzed using Kaplan-Meier survival curves and the statistical comparisons 
were made with a Gehan-Breslow-Wilcoxon test. Experiments were done in 
duplicate with the exception of those on WT, untreated mutants, 0.1% Mpe- and 
0.01% L-Dopa-treated PINK1
B9
 that were done in triplicate. Each experiment was 
conducted with the appropriate control group (i.e. WT, untreated PINK1
B9
 and 
treated PINK1
B9
). 
Climbing assay 
The climbing assay (negative geotaxis assay) was used to assess locomotor ability 
[17]. Climbing data were obtained from groups I–III of untreated WT, untreated 
PINK1
B9
 and, as L
+
/A
+
, 0.1, 1 and 10% Mpe- and 0.01% L-Dopa-treated PINK1
B9
 
mutants. Cohorts of 30 flies from each experimental group were subjected to the 
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assay. Flies were placed individually in a vertically-positioned plastic tube (length 
10 cm; diameter 1.5 cm) and tapped to the bottom. Climbing time was recorded 
upon crossing a line drawn at 6 cm from the bottom. The number of flies that could 
climb unto, or above, this line within 10 seconds was recorded and expressed as 
percentage of total flies. Data were expressed as average + SEM from at least three 
separate experiments. The statistical evaluation was made by two-way ANOVA 
(p<0.05) followed by HSD post-hoc test. 
Electroantennograms (EAGs) recordings 
In vivo electroantennogram recordings (EAG) were performed following a 
previously described protocol [4]. Briefly, live adult WT Dm and untreated, Mpe- 
and L-Dopa-treated PINK1
B9
 from group II (n = 12/each strain) were singly 
positioned under the view of an Olympus BX51WI light microscope (Olympus, 
Tokyo, Japan). Electrodes were silver wires inserted in glass capillaries filled with 
a saline solution (NaCl 150 mM).The recording glass electrode was positioned on 
the tip of the left antenna while the reference was pierced through the compound 
eye. The EAG signal was amplified with an AC/DC probe and then acquired with 
an IDAC-4 interface board (Syntech, Hilversum, NL). The antennae were 
constantly blown by a flow of charcoal purified and humidified air (speed 0.5 m/s) 
via a glass tube. Odor stimuli were administered by injecting a puff of purified air 
(0.5 s at 10 mL/s airflow) through the pipette using the stimulus delivery controller 
(Syntech, Hilversum, NL). 
Odor stimuli were prepared in 3 step-dose concentration (0.01, 0.1, and 1% v/v) 
diluted in hexane. Odor stimulus, 1-hexanol, was chosen according to Fishilevich 
and Vosshall [20], for its well-known stimulant activity in Dm. Mean values of 
EAG amplitude were calculated and then analyzed by comparing the results 
obtained in untreated PINK1
B9
, Mpe- and L-Dopa-treated flies with matched WT. 
The significance of differences was tested by one-way ANOVA (followed by HSD 
post hoc test) with a threshold level of statistical significance set at p<0.05. EAG 
results are expressed as average values ± S.E.M and represented by histograms. 
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Olfactory behavior 
Free-walking bioassay was performed following the experimental procedures used 
by Dekker et al. [18]. In particular, group II WT, untreated PINK1
B9
 and, as L
+
/A
+
, 
0.1% Mpe- and 0.01% L-Dopa-treated PINK1
B9
 mutants were given the 
opportunity to choose between vials containing water with or without odor. Two 4 
mL glass vials were placed symmetrically in a large petri dish (arena) and then 
fitted with truncated pipette tips. The vials were filled with 300 µL of water with 
0.25% Triton X (Sigma-Aldrich, Milan, Italy) with or without the odorant (0.1% 
(v/v) 1-hexanol; Sigma-Aldrich, Milan, Italy). As mentioned above, in order to 
allow detection of possible Mpe’s effects independently from the circuit, 
octopaminergic -for appetitive- and dopaminergic -for aversive stimuli [19], 1-
hexanol was chosen, according to Fishilevich and Vosshall [20], because the 
mechanism(s) of olfactory transduction signal involve several glomeruli and 
complex neural pathways. Flies were starved for 8 hours prior to starting the 
experiments. These, done in triplicate, were performed in controlled environmental 
conditions (n = 12 bioassays/each experimental group of flies; n = 20 flies/arena). 
The assays lasted 18 hours, a streamlined range of time to overtake the possible 
influence of motor impairment in mutants. The dehydration of flies was prevented 
by placing a cotton ball with 3 mL of water in the arenas. Data obtained were 
expressed as average of percentages of flies reaching the 1-hexanol or water trap 
and statistically evaluated by one-way ANOVA (p<0.05) followed by HSD post-
hoc test. 
Electron microscopy analysis 
Group II WT, untreated PINK1
B9
 and, as L
+
/A
+
, 0.1% Mpe-treated PINK1
B9
 
mutants were anesthetized using carbon dioxide and carefully decapitated. The 
brains and the thoracic ganglia, once rapidly removed, were fixed in a mixture of 
2% glutaraldehyde and 2% paraformaldehyde in 0.1 M cacodylate buffer, washed 
several times in the same buffer, post-fixed in 1% osmium tetroxide in distilled 
water for 2 hours, and stained overnight at 4°C in an aqueous 0.5% uranyl acetate 
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solution. After several washes in distilled water, the samples were dehydrated in a 
graded ethanol series, and embedded in SPURR resin. To identify the antennal 
lobes (ALs), semi-thin coronal sections of the whole brains were cut with a Leica 
EM UC6 ultramicrotome, stained with toluidine blue and observed with a Leica 
DM2700 P light microscope. Sections of about 70 nm corresponding to portions of 
the ALs and thoracic ganglia were cut with a diamond knife on a Leica EM UC6 
ultramicrotome. Transmission electron microscopy (TEM) images were collected 
with a FEI Tecnai G2 F20 (FEI Company, The Netherlands) and a Jeol JEM 1011 
(Jeol, Japan) electron microscopes, working respectively at an acceleration voltage 
of 80 and 100 kV, and recorded with a 1 and 2 Mp charge-coupled device (CCD) 
camera (Gatan BM Ultrascan and GatanOrius SC100, respectively). T-bars density 
(expressed as number of T-bars/m
2
) in both ALs and thoracic ganglia presynaptic 
boutons was assessed on a total of ten animals (three WT, three untreated PINK1
B9
 
and four 0.1% Mpe-treated PINK1
B9
 mutants). 459 and 683 T-bars were randomly 
sampled respectively in the ALs and the thoracic ganglia on a total 496 non-
overlapping micrographs at a final magnification of 6000, corresponding to a total 
sampled area of more than 6000 µm
2
. T-bars were unambiguously identified at 
presynaptic active zones by the presence of T-shaped electron-dense projections 
typically tethered by a large number of presynaptic vesicles. 
The number of damaged mitochondria within ALs (expressed as percentage of the 
total number of mitochondria/sampled area) was evaluated in WT, untreated 
PINK1
B9
 and 0.1% Mpe-treated PINK1
B9
 mutants. More than 3000 mitochondria 
were randomly sampled on 191 non-overlapping micrographs at a final 
magnification of 4000, corresponding to a total sampled area of more than 5000 
µm
2
. Damaged mitochondria were recognized for the presence of swollen external 
membrane, clearly fragmented cristae and inhomogeneous electron transparent 
mitochondrial matrix. The mean differences were tested using a two tailed t-test 
and a p<0.01 level was considered statistically significant. 
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Protein extraction and western blot analysis 
Group II WT, untreated PINK1
B9
 and, as L
+
/A
+
, 0.1% Mpe- and 0.01% L-Dopa-
treated PINK1
B9
 mutants flies were collected and immediately stored at −80°C. 
Head lysate preparations of adult males were performed by homogenization in 
RIPA buffer (9.1 mmol/L dibasic sodium phosphate, 1.7 mmol/L monobasic 
sodium phosphate, 150 mmol/L sodium chloride, 1% Nonidet P-40, 0.5% sodium 
deoxycholate, 0.1% sodium dodecylsulfate [pH adjusted to 7.4]) containing fresh 
protease inhibitor cocktails (Sigma-Aldrich, St. Louis, MO, USA). Two 
centrifugations were performed at 4°C at 10,000 g for 15 minutes, before protein 
quantification by DC Protein assay (Biorad, Hercules, CA, USA). 20 µg of 
proteins were resolved by sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis analysis using the mini-PROTEIN 3-electrophoresis module 
assembly (Biorad, Hercules, CA, USA) and then transferred to immobilon-
polyvinylidenedifluoride membranes (Amersham Biosciences). The membranes 
were incubated with primary antibodies overnight at 4°C. Immune complexes were 
detected with horseradish peroxidase–conjugated secondary antibodies and 
chemiluminescence reagents (ECL, Amersham Biosciences) and visualized by 
Image Quant LAS 4000. Densitometric analysis was performed by Image Studio 
Lite software for quantitative assessment. 
Primary antibodies used in this study were against nc82 (1∶100 dilution, DSHB); 
Tyrosine Hydroxylase (1∶1000 dilution, MAB 318 Merk Millipore); actin (1∶100, 
sc1616 Santa Cruz Biotechnology); Horseradish-peroxidase–conjugated secondary 
antibodies were purchased from Life Technologies. Statistical significance of the 
results was evaluated by one-way ANOVA (p<0.05) followed by a HSD post-hoc 
test. 
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Results 
Effects of Mucuna pruriens and L-Dopa on life span of 
PINK1
B9
 mutants 
As shown in Fig. 1A, in agreement with our previous report [4], PINK1
B9
 mutants 
displayed a significantly shorter lifespan with respect to WT flies. To assess the 
ability of Mpe to affect lifespan of PINK1
B9
 mutants, they were supplied Mpe at 
different concentrations (0 (untreated), 0.1, 1 and 10% w/w in their standard diet) 
both as adults only (L
−
/A
+
) (Fig. 1B and Fig. S1A), and as larvae and adults 
(L
+
/A
+
) (Fig. 1C and Fig. S1B). The effects of L-Dopa (supplied as L
+
/A
+
 at the 
concentration, 0.01%, at which is present in the Mpe 0.1%) on life span of 
PINK1
B9
 are also reported in Fig. 1D. The comparison between untreated and Mpe-
treated PINK1
B9
, as shown by Kaplan-Meier survival curves, revealed a 
statistically significant effect of Mpe on lifespan of PINK1
B9
 mutants only when 
L
+
/A
+
 flies were fed 0.1% Mpe (Fig. 1C, p<0.05 by Gehan-Breslow-Wilcoxon 
test). No effect was observed following the L-Dopa administration in L
+
/A
+
.         
As shown in Fig. S1A, no significant effects were detected in in L
−
/A
+
 flies, no 
matter the concentration tested, nor in L
+
/A
+
 flies fed 1% or 10% Mpe enriched 
standard diet (Fig. S1B). 
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Figure 1. Effects of Mpe and L-Dopa on lifespan. 
(A): Lifespan, expressed as % survival rates, of wild type (WT) and PINK1
B9
 flies. 
(B) and (C): Lifespan of PINK1
B9
 treated with Mucuna pruriens extract (Mpe) 
0.1%,only when adults (L
−
/A
+
) (panel B) or from their larval stage to the end of 
their life-cycle (L
+
/A
+
) (panel C), respectively, as compared to lifespan of 
untreated PINK1
B9
 flies. (D): Lifespan of PINK1
B9
 flies treated with L-Dopa 
(L
+
/A
+
) 0.01%. *indicates p<0.05 at Kaplan-Meier survival curves (Gehan-
Breslow–Wilcoxon - GraphPad Prism 5.01) between WT and untreated PINK1B9 
(A) and between untreated PINK1
B9
 and PINK1
B9
 fed Mpe 0.1% (C). 
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Mucuna pruriens rescues impaired climbing behavior of 
PINK1
B9
 mutants 
To investigate the locomotor ability the negative geotaxis assay, as described 
previously [17], was used. An impairment of climbing behavior was observed in 
untreated PINK1
B9
 at different age steps (I: 3–6; II: 10–15; III: 20–25 days old) 
with a worsening trend with aging, while WT flies fulfilled the evaluation criterion 
without differences among age groups.  
As shown in Fig. 2A, the mutants took longer times to accomplish the task than the 
WT (p<0.001). The Mpe 0.1% treatment significantly ameliorated the climbing 
activity in mutants and also reduced the worsening trend with aging although the 
score obtained by treated mutants still remained higher than that measured in WT. 
Interestingly, the climbing time of L-Dopa-treated mutants from groups I and III 
did not significantly differ with respect to age-matched untreated PINK1
B9
, the 
performance of only group II flies being significantly ameliorated. 
As shown in Fig. 2B, L
+
/A
+
 1% Mpe-treated mutants reached similar rescue of 
climbing activity as observed in 0.1% Mpe-treated ones only when tested at early 
ages (groups I and II). On the other hand, 10% Mpe administration failed to 
significantly ameliorate motor behavior in groups I and III with respect to 
untreated PINK1
B9
 mutants, while a significant effect was detected in treated flies 
from group II. We also considered the percentages of flies that were able to 
complete the test and the results are depicted in histograms shown in Fig. 2C and 
D. In this respect, most of WTs of all age steps (97–98%) were able to complete 
the test, while only 76% of PINK1
B9
 from group I, 46% from group II and 36% 
from group III accomplished it, showing a clear age-dependent worsening. 
Administration of 0.1% Mpe, as L
+
/A
+
, greatly rescued PINK1
B9
 mutants (groups 
I–III) from motor impairment and restored to WT values the percentages (86–94%) 
of flies able to accomplish the task according to the evaluation criterion (10 sec). 
Furthermore, at variance with the above results, the effects of L-Dopa worsened 
over time. In particular, 0.01% L-Dopa administration determined a decrease of the 
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number of flies able to complete the task showing a negative trend with aging. In 
fact, percentages of flies were 91%, 82% and 62%, in groups I, II and III, 
respectively. 
 
 
Figure 2. Effects of Mpe and L-Dopa on climbing activity. 
(A): Climbing activity of adult males wild-type (WT), untreated PINK1
B9
, 
PINK1
B9
 treated with Mucuna pruriens extract (Mpe) 0.1% and PINK1
B9
 treated 
with L-Dopa 0.01% (L-Dopa 0.01%). (B): Climbing activity of PINK1
B9
 adult 
males treated with Mpe 1 and 10% as compared with WT and untreated PINK1
B9
. 
(A) and (B): Treatments were administered to flies from their larval stage to the 
end of their life-cycle (L
+
/A
+
) and their effects were assayed at three different age 
steps (I: 3–6; II: 10–15; III: 20–25 days) of flies’ life-span. Values are average + 
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SEM. *indicates p<0.05 at two-way ANOVA followed by HSD post-hoc test as 
compared to WT; **indicates p<0.05 at two-way ANOVA followed by HSD post-
hoc test as compared to PINK1
B9
; ***indicates p<0.05 at two-way ANOVA 
followed by HSD post-hoc test as compared to PINK1
B9
 Mpe 0.1%. (C) and (D): 
Percentages of adult males WT, PINK1
B9
, Mpe 0.1%, L-Dopa 0.01% (C) and Mpe 
1 and 10% (D) that could climb unto, or above, the line drawn at 6 cm from the 
bottom of the tube within 10 seconds. 
 
Mucuna pruriens and L-Dopa effects on the EAG amplitude 
As expected, the olfactory stimulations of flies’ antennae elicited responses with 
the typical EAG wave form, i.e. a rapid depolarization followed by a slower 
recovery phase, ending with the hyperpolarized wave before complete reversal to 
the baseline. 
The results, summarized in Fig. 3A and 3B, show the olfactory response to            
1-hexanol (0.01, 0.1 and 1%) elicited in WT, untreated PINK1
B9
, 0.1% Mpe- and 
0.01% L-Dopa-treated mutants from age group II. In details, the average EAG 
signal amplitudes evoked by stimuli were significantly lower in PINK1
B9
 
specimens in respect to WT thus substantially confirming data previously reported 
[4]. The stimulation with 1-hexanol at 1% did not elicit a significant increase in the 
EAG amplitude as compared with the stimulation at 0.1% in all strains of flies with 
the exception of mutants flies treated with L-Dopa 0.01%. This result indicates that 
at the highest odor concentrations (0.1 and 1%) a saturation of response was 
reached by all groups but by the L-Dopa treated mutants. Besides, we observed 
that the responses to stimuli in WTs elicited a greater hyperpolarized phase in the 
EAGs (Fig. 3B and S2). 
Even if a positive trend in treated mutants exists in the signal amplitude in response 
to 1-hexanol, a statistical difference between untreated, Mpe- and L-Dopa-treated 
PINK1
B9
 was not detected. The lowest odor concentration tested elicited a 
significantly higher response in WT as compared to the all strains of mutants 
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(p<0.05). This difference shrank when the 0.1% concentration of odor was 
administered. A reduced response, although not statistically significant (p>0.05), 
was still detected in untreated mutants with respect to WTs (p<0.05), while treated 
flies showed on average an increased response with respect to untreated flies. The 
response measured in treated flies was therefore halfway between the highest of 
WTs and the lowest of untreated PINK1
B9
. Samples of EAGs responses are shown 
in Fig. 3B and Fig. S2. 
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Figure 3. Electroantennogram responses to 1-hexanol. 
Histograms in (A) show the dose-response relationship and their differences in 
signal for olfactory stimulations in WT, untreated PINK1
B9
 and in Mpe (0.1%)- 
and L-Dopa (0.01%)-treated PINK1
B9
, recorded in flies from group II. As odor 
stimuli, the 1-hexanol was administered in a 3-step dose from 0.01 to 1% in 
hexane. Values are average + SEM. *indicates p<0.05 at one-way ANOVA 
followed by HSD post hoc test as compared to the previous concentration of the 
stimulus. **indicates p<0.05 at one-way ANOVA followed by HSD post-hoc test 
as compared to WT. (B) Samples of EAGs recordings in response to 1-hexanol 
0.1%. 
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Mucuna pruriens rescues impaired olfactory behavior 
The olfactory behavior assay was restricted to flies of group II, by testing the 
responses to 1-hexanol (0.1% v/v) of WT, untreated PINK1
B9
, 0.1% Mpe- and 
0.01% L-Dopa-treated, as L
+
/A
+
, PINK1
B9
 mutants. As expected, the analysis of 
the result, shown in Fig. 4, confirmed the olfactory behavioral impairment in 
PINK1
B9
 flies [4]. In fact, only 29.6±4.4% of mutant flies were odor-trapped, while 
the percentage of baited WT (52.9±6.6%) was significantly higher (p<0.004). 
PINK1
B9
 flies treated with 0.1% Mpe and 0.01% L-Dopa were able to reach the 
stimuli as WT controls (p>0.05). In fact, percentages of trapped flies were 
45.2±5.8% and 44.2±3.6% for 0.1% Mpe- and 0.01% L-Dopa-treated mutants, 
respectively. Similar results were obtained concerning the numbers of trapped flies 
in the blank bait (H2O) (p<0.05 between untreated PINK1
B9
with respect to WT, 
0.1% Mpe- and 0.01% L-Dopa-treated mutants). 
 
 
Figure 4. Effects of Mpe and L-Dopa on olfactory behavior. 
Responses to 1-hexanol 0.1% and water (H2O) of WT, untreated PINK1
B9
 and in 
Mpe (0.1%)- and L-Dopa (0.01%)-treated PINK1
B9
 flies. Values are average + 
SEM. *indicates p<0.05 at two-way ANOVA followed by HSD post hoc test as 
compared to WT, PINK1
B9
 Mpe 0.1%, PINK1
B9
 L-Dopa 0.01%. 
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Mucuna pruriens rescues loss of T-bars at active zones of 
presynaptic terminals and damaged mitochondria in the 
antennal lobes and thoracic ganglia 
Transmission electron microscopy (TEM) analysis was restricted to flies of group 
II of untreated WT, untreated PINK1
B9
 and 0.1% Mpe-treated, as L
+
/A
+
, PINK1
B9
 
mutants and results are shown in Fig. 5. A significant decrease of T-bars density 
was observed in the presynaptic bouton active zones of both ALs and thoracic 
ganglia of PINK1
B9
 mutants with respect to WT controls (panels A, B, E and F). 
More importantly, a significant increase of T-bars density was detected in the ALs 
and thoracic ganglia of PINK1
B9
 treated with 0.1% Mpe, as L
+
/A
+
, with respect to 
untreated PINK1
B9
 (panels A, B, E and F). Moreover the number of damaged, 
swollen and with clearly fragmented cristae, mitochondria was significantly lower 
in presynaptic boutons of ALs of PINK1
B9
 mutants treated with 0.1% Mpe, 
compared with untreated mutants (panels C, D and G). 
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Figure 5. Effects of Mpe on T-bars and mitochondria in antennal lobes and thoracic 
ganglia. 
Transmission electron microscopy (TEM) images of T-bars and mitochondria 
inside antennal lobes (ALs) of wild type (WT), untreated PINK1
B9
 and in Mpe 
(0.1%)-treated PINK1
B9
 flies. (A): T-bars in a presynaptic bouton of PINK1
B9
 ALs 
(arrowheads). Asterisks indicate mitochondria inside presynaptic boutons and 
neurites. Inset: high magnification of two T-bar in coronal section. (B): T-bars in 
presynaptic boutons of ALs of PINK1
B9
 Mpe 0.1% (arrowheads). Asterisks 
indicate mitochondria inside presynaptic boutons and neurites. (C): swelling on the 
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external mitochondrial membrane (at high magnification in the inset) and 
mitochondrial cristae widely degenerated (asterisks) in ALs of PINK1
B9
.            
(D): Mitochondria of PINK1
B9
 Mpe 0.1% (asterisks). (E): Presynaptic T-bar 
density in ALs of WT, PINK1
B9
 and PINK1
B9
 0.1% Mpe flies. Values are average 
+ SEM. *indicates p<0.01 at two tailed t-test with respect to PINK1
B9
. (F): T-bar 
density in thoracic ganglia of WT, PINK1
B9
 and PINK1
B9
 0.1% Mpe flies. Values 
are average + SEM. *indicates p<0.01 at two tailed t-test with respect to PINK1
B9
. 
(G): Percentages of damaged mitochondria in ALs of WT, PINK1
B9
 and PINK1
B9
 
0.1% Mpe flies. Values are average + SEM. *indicates p<0.01 at two tailed t-test 
with respect to PINK1
B9
. Abbreviations: postsyn: postsynaptic; presyn: 
presynaptic. Scale bars are 200 µm in A and B and 500 µm in C and D. 
 
Mucuna pruriens and L-Dopa differentially affect whole 
brain bruchpilot (BRP) and tyrosine hydroxylase (TH) 
expression 
Fig. 6 shows the results of western blot analysis of whole brain expression of BRP 
and TH of flies of group II WT, untreated PINK1
B9
 0.1% Mpe- and 0.01% L-Dopa-
treated, as L
+
/A
+
, PINK1
B9
 mutants. As shown in Fig. 6A, the expression of BRP 
and TH in untreated PINK1
B9
 mutants was significantly lower (p<0.05) than in 
WT. Diet supply of 0.1% Mpe to PINK1
B9
 mutants significantly recovered BRP 
and TH expression to WT controls levels (p<0.05) and these values did not differ 
statistically from those of WT. Notably, BRP and TH expression in PINK1
B9
 
mutants fed 0.01% L-Dopa resulted similar to BRP and TH expression in untreated 
PINK1
B9
 mutants. ANOVA also revealed that both BRP and TH expression 
resulted statistically different as compared to their expression of both WT and 
PINK1
B9
 mutants fed 0.1% Mpe. 
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Figure 6. Effects of Mpe and L-Dopa on BRP and TH. 
(A): Representative western blot analysis of head homogenates from adult wild 
type (WT), untreated PINK1
B9
 and in Mpe (0.1%)- and L-Dopa (0.01%)-treated 
PINK1
B9
 flies showing labeled bands of Bruchpilot protein (BRP), of Tyrosine 
hydroxylase (TH) and of the loading control actin (from top to bottom).              
(B): Percentage of protein expression variation of BRP and TH in WT, untreated 
PINK1
B9
 and in Mpe (0.1%)- and L-Dopa (0.01%)-treated PINK1
B9
 flies. Values 
are average + SEM. *indicates p<0.05 at one-way ANOVA with respect to WT; 
**indicates p<0.05 at one-way ANOVA (HSD post-hoc test) with respect to 
PINK1
B9
 Mpe 0.1%. 
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Discussion 
This study was aimed at characterizing the effects of the standardized extract of 
Mucuna pruriens seeds, known for possible neuroprotective effects in neurotoxin-
induced models of PD [21] [22] and reduced risk of dyskinesias [14], in a genetic 
fly model of PD, the PINK1
B9
 mutant Dm [23]. Notably, mutations at PINK1 gene 
model a number of features of early onset PD such as cell energy maintenance [24] 
and compromised olfactory and mitochondrial function [4] enabling in-depth 
investigations into physiopathology of PINK1
B9
-related molecular, morphological 
and functional bases of PD.  
The present results show that addition of 0.1% Mpe to the feeding medium of 
PINK1
B9
 mutants significantly a) improved climbing ability and olfaction, b) 
rescued compromised T-bars density and damaged mitochondria in the ALs and 
thoracic ganglia, c) restored to WT control values the expression of BRP and TH 
proteins. Moreover, these results suggest that Mpe is an effective medication with 
intrinsic ability of delaying the onset of chronic L-Dopa-induced long-term motor 
complications (Fig. 2A and B). These findings are in general agreement with 
previous studies reporting antiparkinsonian activity of Mp [14] [25] associated with 
reduced risk of dyskinesias, both in the clinical [26] and in the experimental [14] 
setting, and suggest that its antiparkinsonian effects may be due to components 
other than L-Dopa or that its components might have L-Dopa-enhancing effects 
[25] [26] [27] on one hand, as well as L-Dopa-induced dyskinesias (LID)-
preventive effects, on the other. Intriguingly, PINK1
B9
 mutations have been linked 
to both autosomal recessive and sporadic forms of PD and, given the role of 
PINK1-parkin pathway in regulating mitochondrial function, our findings highlight 
its role as a potential target for the described actions of Mpe [30] on mitochondria. 
This interpretation finds further support in the observation of mitochondrial stress-
dependent neurodegeneration [7] and dysfunction in PINK1 knock-out mice [31]. 
A large body of literature documents that mutations of PINK1 gene are associated 
with mitochondrial dysfunction. In particular, complex I deficiency [24] [32] has 
46 
 
been characterized as a mechanism of energy balance failure [33] resulting also in 
dramatic loss of dopaminergic neurons [34]. Although in the present study we did 
not attempt any direct measurement of mitochondrial energy impairment, this 
dysfunction was indirectly determined by assessing the number of damaged, 
swollen and with clearly fragmented cristae, mitochondria and we found that 0.1% 
Mpe administration could dramatically recover their morphology to that of WT 
controls (Fig. 5). This indicates that Mpe may play beneficial actions by interfering 
with the mechanisms responsible of energy production [24] or linked to 
maintenance of membrane gradients as well as to protection against the raise of 
reactive oxygen species within mitochondria [16]. In this regard, it is intriguing to 
observe that Mp has antioxidant properties [35] and it was suggested that its 
“rescue” properties may be due to increased complex-I activity and presence of 
nicotinamide adenine dinucleotide and coenzyme Q-10 [25]. This interpretation is 
also supported by the observation that also enhancement of nucleotide production, 
by feeding PINK1 mutant Dm with folic acid, results in rescued loss of 
mitochondrial mass and function [31].  
Thus, on the basis of these reports and of our results it seems possible to speculate 
that Mpe administration interferes with the pathway regarding the mitochondrial 
rescue from oxidative stress but not on the complex apoptosis mechanism. In fact, 
the clock of the end of the life is not modified as also suggested by the results 
regarding the effect of Mpe on life span according to which the amelioration is 
slight, albeit significant. In agreement with Poddighe et al. [4], PINK1
B9
 mutants 
showed steeper slope life span curves and overall shortened lifespan with respect to 
WT. Mpe significantly attenuated these conditions only when administered to 
L
+
/A
+
 at 0.1%, but not when administered to adults only (L
−
/A
+
) no matter the 
concentration tested (Fig. S1A), nor when administered with 0.01% L-Dopa. These 
results can be explained by taking into account that in Drosophila the cluster of 
neurons is manly conserved from larval to adult stage [28]. Conversely in L
+
/A
+
 
mutants treated at the highest concentration administered (1–10%) even if not 
significant, a worsening trend was observed (Fig. S1B). The effects of Mpe on 
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flies’ lifespan resemble those of the Mpe component, nicotine, described in a 
Drosophila autosomal recessive-juvenile model of parkinsonism [29]. 
In addition to the observed rescue of damaged mitochondria in PINK1
B9
 mutants 
treated with 0.1% Mpe, we observed that this treatment significantly recovered the 
expression of BRP and the reduction of T-bars density in both PINK1
B9
 ALs and 
thoracic ganglia, strengthening the tenet that BRP is crucial for the correct 
formation of T-bars at active zones [36]. Mutation-induced mitochondrial 
degeneration may also have led to the observed diminished expression of BRP, 
known to be critical also for neurotransmitter release [37] [38]. Accordingly, 
PINK1
B9
 mutants show degeneration of flight muscle and of dopaminergic neurons 
accompanied by locomotive defects [23] [39] [40]. Humphrey et al. [40] also 
showed that climbing deficit is related to dysfunction of dopaminergic cells and we 
found that PINK1
B9
 mutants also showed compromised motor capabilities as 
assessed by climbing behavior (Fig. 2). Hence, Mpe-increased expression of BRP 
may have increased the ability to release neurotransmitters that would result in 
improved locomotion, as suggested by Yellman et al. [41]. Therefore, our data 
suggest that the effects of Mpe treatment on BRP expression, climbing and T-bars 
in PINK1
B9
 mutants may represent the convergence toward an unified mechanism 
grounded on mitochondria functional rescue. 
Olfactory dysfunction is a clinical early non-motor symptom of PD [3] and, 
accordingly, we observed loss of olfaction in PINK1
B9
 mutant Dm [4]. The 
physiopathology of olfactory dysfunction is not known. However, many studies 
have suggested involvement of dopaminergic system [42] [43]. In our investigation 
we observed improved olfactory responsiveness underlined by both behavioral and 
electrophysiological experiments. It is interesting to observe that the shape of EAG 
responses recorded in the WT revealed a dose-related hyperpolarizing part (Fig. 
S2). This observation seems in accordance with the stimulating power of 1-hexanol 
that is reported to involve both the appetitive and the aversive stimuli [19]. The 
EAG represent the summed activity of all antennal sensory neurons involved in 
stimulation. This activity can result in the EAG recordings in a depolarization 
and/or hyperpolarization signal, that is elicited according to the stimulating effect 
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of the odor tested as well as of its concentration. In details, in WT strain, the rapid 
depolarization is followed by a slow recovery phase at the lower concentration 
(0.01%) while at the highest concentration (1%), a greater hyperpolarizing phase 
was recorded. This phase could represent the activation of a pool of receptors that 
hyperpolarize when stimulated at this high concentration. With regards to this, a 
similar response was not present in untreated PINK1
B9
 (Fig. S2). Future 
electrophysiological analysis of the olfactory response should take into account 
both shape and amplitude whose variations might be a promising tool to study 
peripheral olfactory responses. Furthermore, our behavioural results show that 
PINK1
B9
 mutants have a decreased responsiveness to 1-hexanol and water (Fig. 4) 
that reveals an impairment of also other chemoreceptors such as hygroreceptors 
[44]. In other words the mutants seem to present a general sensory impairment.    
In agreement with study by Katzenschlager and Lees [45], suggesting a possible 
association between olfaction, increased TH and dopamine in the olfactory bulbs, 
we observed that PINK1
B9
 mutation-dependent impairment of olfaction behavior 
and whole brain TH expression were improved by Mpe treatment (Figs. 4 and 6, 
respectively). Surprisingly, L-Dopa administration on its own failed to recover TH 
expression to WT controls levels. However, since our analysis was done in whole 
brain homogenates, if analysis was restricted to the ALs, the homologous 
structures of human olfactory bulbs, we cannot exclude the possibility that L-Dopa 
would have brought different results. The physiopathology of LID is still largely 
unknown and LID has consistently been related to excessive DA release [46]. 
Furthermore, in parkinsonian non-human primates [47], L-Dopa produces LID 
without enhancing striatal DA release. Interestingly, Katzenschlager et al. [26] 
observed a reduced severity of dyskinesias after Mp as compared to 
levodopa/carbidopa combination and an increased DDC expression associated with 
LID has been reported in rats [48]. This intriguing prospective remains to be fully 
demonstrated in the Dm mutant model. In conclusion, our study confirms in this 
translational model the validity of Mucuna pruriens as a valuable approach for PD 
treatment, discloses mechanistic insights at the basis of its effects and confirms the 
use of PINK1
B9
 Dm as a model of PD that fulfills the required face, construct and 
predictive validity criteria to follow up on these investigations. 
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Supporting Information 
 
 
 
Figure S1. Effects of Mpe administered at different concentration on lifespan.  
(A): Lifespan, expressed as % survival rates of untreated and Mpe-treated PINK1
B9
 
at the 4 dose-step tested: 0, 0.1, 1 and 10% (w/w) only when adults (L
−
/A
+
).  
(B): lifespan of untreated and Mpe-treated PINK1
B9
 at the 4 dose-step tested: 0, 
0.1, 1 and 10% (w/w) only when adults (L
+
/A
−
). 
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Figure S2. EAGs samples.  
Dose-response relationships for olfactory stimulations in WT and PINK1
B9
 adult 
flies and their differences in signal amplitude and shape. 
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Section 2 
 
Drug effects of Withania somnifera in a LRRK2 
Drosophila model 
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Abstract 
The common fruit fly Drosophila melanogaster (Dm) is a simple animal species 
that contributed significantly to the development of neurobiology whose leucine-
rich repeat kinase 2 mutants (LRRK2) loss-of-function in the WD40 domain 
represent a very interesting tool to look into physiopathology of Parkinson’s 
disease (PD). Accordingly, LRRK2 Dm have also the potential to contribute to 
reveal innovative therapeutic approaches to its treatment. Withania 
somnifera Dunal, a plant that grows spontaneously also in Mediterranean regions, 
is known in folk medicine for its anti-inflammatory and protective properties 
against neurodegeneration. The aim of this study was to evaluate the 
neuroprotective effects of its standardized root methanolic extract (Wse) on the 
LRRK2 loss-of-function Dm model of PD. To this end mutant and wild type (WT) 
flies were administered Wse, through diet, at different concentrations as larvae and 
adults (L
+
/A
+
) or as adults (L
-
/A
+
) only. LRRK2 mutants have a significantly 
reduced lifespan and compromised motor function and mitochondrial morphology 
compared to WT flies 1% Wse-enriched diet, administered to Dm LRRK2 as         
L
-
/A
+
and improved a) locomotor activity b) muscle electrophysiological response 
to stimuli and also c) protected against mitochondria degeneration. In contrast, the 
administration of Wse to Dm LRRK2 as L
+
/A
+
, no matter at which concentration, 
worsened lifespan and determined the appearance of increased endosomal activity 
in the thoracic ganglia. These results, while confirming that the LRRK2 loss-of-
function in the WD40 domain represents a valid model of PD, reveal that under 
appropriate concentrations Wse can be usefully employed to counteract some 
deficits associated with the disease. However, a careful assessment of the risks, 
likely related to the impaired endosomal activity, is required.  
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Introduction 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder 
[1] affecting 2% of the population over 60 years with an increasing incidence over 
age 85 [2]. The progressive loss of dopaminergic neurons in the substantia nigra of 
the midbrain leads to a deficiency of dopamine causing the typical motor 
symptoms such as tremor, bradykinesia and rigidity [3][4]. Although the 
etiopathogenesis is not fully understood and most cases seem sporadic, genetic 
variables play a key role in the predisposition to PD onset with at least 5 to 10% of 
PD patients clearly associated with genetic factors [5]. Indeed, since the seminal 
paper of Polymeropoulos et al. [6], which identified the first mutation related to PD 
in the alpha-synuclein gene, other genes involved in the etiology of familial forms 
of parkinsonism have been discovered [7–15]. Among them, the identification of 
several leucine-rich repeat kinase 2 (LRRK2) gene mutations has opened a novel 
scenario in Parkinson’s disease genetics [16]. In fact, the G2019S LRRK2 
mutation is the most common in Caucasian  patients occurring in 1–2% of sporadic 
cases of PD [17][18], while other mutations, such as the G2385R variants 
contribute to the susceptibility to develop PD especially in Chinese patients [19]. 
LRRK2 encodes for a protein with a number of independent domains that is 
expressed, although at a low level, in all tissues. In the brain it is found in the 
cortex, striatum, hippocampus, cerebellum, and at the level of the dopaminergic 
neurons in the substantia nigra [20–23]. Most mutations of this gene are associated 
with a late onset Parkinsonism [15]. Mutations of the gene LRRK2 that elicit the 
disease occur at the level of the functional domain Roc (R1441C and G), at the 
level of the COR (Y1699C and R1628P) and of MAPKKK domains (G2019S and 
I2020T) and in only one of the WD40 domains (G2385R) [11][15][24]. This latter 
is known to be crucial in several basic cell functions such as vesicle sorting during 
endocytosis and exocytosis of synaptic vesicles as well as vesicle-mediated 
transport and cytoskeleton assembly [25][26]. The role of the WD40 domain is 
suggested to be crucial in controlling the LRRK2-regulated kinase activity having 
a critical role in the self-interaction and autophosphorylation-mediated mechanisms 
of neuronal toxicity [27]. Accordingly, deletion of this domain has been shown in-
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vitro to cause the reduction of the kinase activity that is restored over-expressing 
the gain of function mutation of the gene [28]. 
Translational animal models are particularly useful in studying neuronal 
dysfunction and investigating the etiology and molecular aspects of 
neurodegenerative diseases. Among the animal species that significantly 
contributed to the development of these studies, the Drosophila 
melanogaster (Dm) represents a simple, yet experimentally and translationally 
powerful, organism that contributed significantly not only to the development of 
neurobiology but also to the progress of knowledge on neurodegenerative diseases. 
Notably, most of the genes implicated in familial forms of PD have a counterpart 
in this insect [29], and Dm mutants of PD have been genetically engineered to 
model key features of the human condition and have been successfully used in 
studying PD pathogenesis and in exploring new strategies of disease treatment 
[30–33]. Previous studies on LRRK2 PD form using Dm mutants (dLRRK2) did 
not clarify the role of LRRK2 in Drosophila, both in mutants gain-of-function for 
the kinase domain [15][34] and loss-of-function (LRRK
ex1
 mutant) [35–37]. 
Fully effective medications to treat neurodegenerative diseases are currently 
lacking and the discovery of novel drug targets for long-sought therapeutics is a 
great challenge for researchers and clinicians. The use of plant extracts is largely 
employed worldwide in traditional medicine, constituting the basis of health care in 
many societies, to treat disparate pathologies [38]. The well-known therapeutic 
properties of the medicinal plants have been investigated in various animal models 
and the observations of such investigations have served in many instances as the 
basis of new drugs development [39][40][33]. A common plant of the Indian flora, 
also found in Southern Europe, including Sardinia (Italy), is Withania somnifera 
(Ws) Dunal. Its roots, used in Ayurvedic medicine for many central nervous system 
disorders [41][42], are a valuable herbal medication and the recognized 
pharmacological effects of Ws, such as anti-oxidant, neuroprotection and 
functional recovery made it of prime interest also in the treatment of PD [43][44]. 
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The aim of this paper was twofold: on one hand to confirm the validity of the 
LRRK
ex1
mutant [35][37], from now on named LRRK2 WD40 loss-of-
function (LRRK2
WD40
), as animal model of parkinsonism in Dm; on the other hand, 
to investigate the antiparkinsonian potential of the standardized methanolic extract 
of Wse roots on this mutant, as compared to Dm wild type (WT, Canton-S). To this 
end we tested lifespan, climbing activity, electrophysiological muscle parameters 
and subcellular ultrastructure (mitochondria and lysosomes) of the neurons 
involved in the motor circuitry, as those present in the Dm thoracic ganglia. 
Materials and Methods 
Fly Strains 
For these experiments we used adult wild type (WT; Canton -S) and LRRK2
WD40 
mutant (LRRK
ex1
, #34750, from Bloomington Stock Center) Drosophila 
melanogaster (Dm) males. After emergence from pupae, WT and LRRK2 mutant 
males were separated. WT and mutant flies were reared on a standard cornmeal-
yeast-agar medium in controlled environmental conditions (24–25°C; 60% relative 
humidity; light/dark = 12/12 hours). In addition, groups of mutant and WT flies 
were reared on a standard medium supplemented with the standardized methanolic 
extract of Withania somnifera root (Wse) (gift of Natural Remedies Ltd, Bangalore, 
India) at three different concentrations (0.1, 1 and 10% w/w) whereas other 
independent groups of WT and mutant flies were reared with 0.01% (0.5 mM)      
L-3,4-dihydroxyphenylalanine (L-Dopa). Wse and L-Dopa were added once the 
mixture was stirred for 10 min and had cooled down sufficiently [45]. All 
treatments were performed in two combinations concerning their life cycle: as 
adults (L
-
/A
+
) or from larvae and adults (L
+
/A
+
). Standard genetic procedures were 
used during the study. 
 
 
63 
 
Survival curves 
With the aim of selecting the optimal Wse’s concentration to perform the whole 
study, Dm were grown on standard diet supplemented with different concentrations 
of Wse at 25°C. Cohorts of 60 flies (6 flies/tube) from each experimental group 
(i.e. Wse-untreated and Wse-treated WT, Wse-untreated and Wse-treated 
LRRK2
WD40
) were monitored every 2 days for their survival. Mortality was 
analyzed using Kaplan-Meier survival curves and the statistical comparisons were 
made with a Gehan-Breslow-Wilcoxon test. All experiments were done in 
triplicate. 
Climbing assay 
The climbing assay (negative geotaxis assay) was used to assess locomotor ability 
[46]. Climbing data were obtained from different age groups (I: 3–6; II: 10–15; III: 
20–25 days old) of untreated-WT, Wse-untreated and Wse-treated 
LRRK2
WD40
 mutants. Cohorts of 30 flies from each experimental group were 
subjected to the assay. Flies were placed individually in a vertically-positioned 
plastic tube (length 10 cm; diameter 1.5 cm) and tapped to the bottom. Climbing 
time (s) was recorded upon crossing a line drawn at 6 cm from the bottom. The 
number of flies that could climb unto, or above, this line within 10 seconds was 
recorded and expressed as percentage of total flies. Data were expressed as average 
± standard error of the mean (SEM) from three experiment replications. 
Statistically significant differences (p<0.05) among WT, Wse-untreated and Wse-
treated LRRK2
WD40
 were indicated. The statistical evaluation was made with a one-
way analysis of variance (ANOVA) followed by LSD post-hoc test. 
Electrophysiological recordings 
At the time of the experiments, flies from group II were anesthetized by using 
CO2 and carefully anchored to a wax support ventral side down, as previously 
reported [47][48] and placed underneath a stereomicroscope. In details, two 
tungsten stimulating electrodes, connected to a stimulator (Master 8, A.M.P.I, 
64 
 
Jerusalem, IL) and a stimulus isolation unit (DS2A, Digitimer Ltd., Hertfordshire, 
UK) were placed into both eyes of the fly in order to activate the Giant Fiber 
System (GFS). Stimulus intensity and duration were adjusted in every single 
experiment until the muscle response was detected; maximal stimulation intensity 
was not greater than 10 V, and stimulus duration was not greater than 0.5 ms. A 
ground tungsten wire was placed into the fly abdomen. A borosilicate recording 
electrode, shaped by a puller (P97, Sutter Instruments, Novato, CA) with a 
resistance of 40-50MΩ when filled with 3M KCl, was placed into the right or left 
backside of the fly in order to record Post Synaptic Potentials (PSPs) from the 
Dorsal Longitudinal Muscle fibers (DLMs). PSPs were recorded with an Axopatch 
2-B amplifier (Axon Instruments, Foster City, CA), filtered at 0.5 kHz and 
digitized at 1 kHz. PSPs were recorded in bridge mode, measured using peak and 
event detection software pCLAMP 8.2 (Axon Instruments, Foster City, CA) and 
analyzed off-line by pCLAMP fit software (Axon Instruments, Foster City, CA). 
All recordings were obtained from at least 10 different flies belonging to each 
experimental group (i.e. WT, Wse-untreated and Wse-treated LRRK2
WD40
). 
Experimenters were blind to the treatment. 
Additional electrophysiological experiments were performed by applying a 
protocol consisting in a single GFS stimulation, delivered every 20 s, followed by 
PSPs recording. In this different set of experiments, the “frequency of following” 
was determined by delivering trains of 10 stimuli at frequencies of 100 Hz (with 10 
ms between stimuli) or 200 Hz (with 5 ms between stimuli). Data are expressed as 
mean + SEM and one or two-way ANOVA followed by Tukey’s or Bonferroni’s 
post-hoc test (p<0.05), were used in order to determine significant differences 
between groups. 
Electron microscopy analysis 
Drosophilae WT, Wse-untreated and Wse-treated at 1% (L
-
/A
+
) and 10% (L
+
/A
+
) 
LRRK2
WD40
from group II were anesthetized with CO2 before brains and thoracic 
ganglia being rapidly dissected out and fixed in a mixture of 2% glutaraldehyde 
and 2% paraformaldehyde in 0.1 M cacodylate buffer. After several rinsing in the 
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same buffer, the samples were post-fixed in 1% osmium tetroxide in 0.1 M 
cacodylate buffer for 2 h and stained overnight at 4°C in aqueous 0.5% uranyl 
acetate solution. Then the samples were washed several times in distilled water, 
dehydrated in a graded ethanol series and then embedded in SPURR resin. 
Roughly 70 nm thick sections, corresponding to portions of the thoracic ganglia 
and antennal lobes (ALs; homologous to olfactory bulbs in vertebrates), were cut 
with a Diatomediamond knife on a Leica EM UC6 ultramicrotome. (Leica 
Microsystems, Germany). Images were obtained with a FEI Tecnai G2 F20 (FEI 
Company, The Netherlands) transmission electron microscope equipped with a 
Shotky field emission gun operating at an acceleration voltage of 80 kV and 
recorded with a 2k x 2k Ultrascan Gatan CCD camera (Gatan, USA). 
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Results 
Effects of Wse on the lifespan of LRRK2
WD40
 
Fig 1A shows that LRRK2
WD40
 mutants exhibit a significantly shorter life span 
than WT controls. To evaluate a possible toxic effect, Wse was tested at different 
concentrations (0.1, 1 and 10% w/w in their standard diet) as L
-
/A
+
 onto WT 
insects. In this respect, no significant effects were detected at 
any Wse concentration but 10% which significantly reduces the duration of life 
(Fig 1B) as compared to untreated WT controls.  
To evaluate the influence of the extract of Wse on the duration of life of the 
LRRK2
WD40
 mutants that, as reported above, demonstrated a reduced life span in 
respect to untreated- WT, they were treated with Wse at the same concentrations as 
L
-
/A
+
 (Fig 1C) or as L
+
/A
+
 (Fig 1D). As shown by the Kaplan-Meier survival 
curves, administration of Wse induces a statistically significant increase, even if by 
a different extent, in the lifespan of mutants LRRK2
WD40
, when the insects were fed 
in the adult stage only at 0.1% and especially 1% concentrations (p<0.05 Breslow-
Gehan-Wilcoxon test). This restoring effect was lost when insects were treated 
at10% Wse L
-
/A
+
 (Fig 1C), and at any concentration when administrated to larvae 
and adults (L
+
/A
+
) LRRK2
WD40
(Fig 1D). The overall results are in accordance with 
the hypothesis that Wse accumulation, due to high concentration and/or long period 
administration, can induce a possible toxic effect. 
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Figure 1. Effects of Wse on lifespan. 
(A): Lifespan, expressed as % survival rates, of wild type (WT) and LRRK2 flies. 
(B): Lifespan of untreated WT compared to treated WT, only when adults (L
-
/A
+
), 
with Wse, 0.1%, 1% and 10%. (C) Lifespan of untreated LRRK2 mutants 
compared to treated LRRK2 mutants, only when adults (L
-
/A
+
), with Withania 
somnifera extract (Wse), 0.1%, 1% and 10%. (D) Lifespan of untreated LRRK2 
mutants compared to treated LRRK2 mutants, from their larval stage to the end of 
their life-cycle (L
+
/A
+
), with Wse, 0.1%, 1% and 10%. *indicates p<0.05 at 
Kaplan-Meier survival curves (Gehan-Breslow–Wilcoxon—Graph Pad Prism 
5.01), (A) untreated LRRK2 compared to untreated WT, (B) untreated WT 
compared to treated WT and (C-D) untreated LRRK2 compared to treated LRRK2. 
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Effect of Wse on the locomotor ability of LRRK2
WD40
 
According to results obtained following Wse administration paralleled with life 
span we decided to test Wse at 1% w/w effects on the climbing activity (negative 
geotaxis) of mutants. Fig 2A shows a significant increase in the climbing time in 
the threeage groups tested (I: 3–6; II: 10–15; III: 20–25 days old) of LRRK2WD40 as 
compared to subjects of the WT group (p<0.001) with a tendency to deterioration 
of the motor performance with aging. The exposure of LRRK2
WD40
 to 1% 
w/w Wse as L
-
/A
+
, induces, in groups I and II, the recovery of motor disability 
showing a significant decrease of time to climb compared to untreated mutants; a 
similar result was also found in insects of groups I-II that were fed 1% Wse from 
larvae and adults (L
+
/A
+
). On the other hand, Wse administration both to L
-
/A
+
 and 
L
+
/A
+
 failed to significantly ameliorate motor behavior in group III aged flies with 
respect to untreated mutants. L
-
/A
+
 flies treated with Wse showed a clear tendency 
toward rescue. 
Moreover, as in zebrafish LRRK2 loss-of-function-WD40, another PD model in 
which a significant rescue of motor impairment after L-Dopa treatment was 
obtained [49] we also tested L-Dopa at 0.01% (0.5 mM) concentration in the 
feeding diet of both L
-
/A
+
 and L
+
/A
+
 mutant flies. The results presented in Fig 
2B show that in Dm mutants the administration of L-Dopa rescued the impairment 
of climbing activity only in insects of group I, while worsening the performance in 
groups II-III. 
We also considered the percentages of flies that were able to complete the test and 
the results are shown in S1 Fig. In this respect, results confirm the rescue of insects 
of groups I-II, treated with Wse both as L
-
/A
+
 and L
+
/A
+
, increase with respect to 
untreated ones. It is noteworthy that the percentage of insects of group II that 
completed the test was 75.2% in WT, 55.6% in untreated mutants, 80.6% in           
L
-
/A
+
 and 69.5% in L
+
/A
+
 Wse-treated mutants. In groupIII, the percentage of 
mutant insects achieving the target was the same no matter the treatment (being 
40.9%, 43.4% and 37.9%, respectively) while more than 52% of WT insects 
accomplished the task, according to the evaluation criterion (10 sec). 
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The percentages of flies that were able to complete the test after L-dopa 
administration are shown in S1B Fig and demonstrate that the worsening was 
positively correlated to age and treatment duration. Thus, the effects of Wse as well 
as those of L-Dopa administration decrease with age but that of L-Dopa was 
drammatic. In fact, group III of L-Dopa-treated flies as L
+
/A
+
 the percentage 
achieving the target was only 15%. 
 
 
 
Figure 2. Effects of Wse on climbing activity. 
(A-B): Climbing activity of LRRK2 adult males treated with Wse 1% as compared 
with WT and untreated LRRK2 (A) and climbing activity of LRRK2 adult males 
treated with L-Dopa 0.01% (0.5mM) as compared with WT and untreated LRRK2 
(B). Values are average ± SEM. * indicates p<0.05 at one-way ANOVA followed 
by LSD post hoc test as compared to WT; ** indicates p<0.05 at one-way ANOVA 
followed by LSD post hoc test as compared to LRRK2. 
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Effects of Wse on the kinetic properties of evoked PSPs 
recorded from DLM in LRRK2
WD40
 
In order to detect potential changes in the function of the DLM neuromuscular 
junction of LRRK2
WD40
 flies, from group II, we first evaluated the basal kinetic 
properties of evoked PSPs (ePSPs) recorded from the DLM after GFS electrical 
stimulation. More precisely, we evaluated the response latency, that is the time 
between stimulation of the GFS and subsequent muscle PSP peak, and PSP peak 
amplitude, that is the maximal muscle depolarization from baseline value. Fig 
3 shows that the basal properties of ePSPs recorded from DLM muscle of WT 
animals results in a latency of 1.84 ± 0.1 ms and in an averaged amplitude of 19 ± 
3 mV.  
Notably, LRRK2
WD40
 mutation results in a significant decrease (21%, p< 0.05) of 
ePSPs latency when compared to WT animals (Fig 3A and 3B). Such effect was no 
longer apparent in LRRK2 (L
-
/A
+
) flies that were treated with Wse 1%. 
Surprisingly, latency in LRRK2 treated flies was significantly higher with respect 
to both WT as well as untreated LRRK2 animals. No significant change was 
detected in PSP peak amplitude among flies from the different experimental groups 
(Fig 3A and 3C). 
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Figure 3. Effect of LRRK2 gene mutation and treatment with Wse 1% (L
-
/A
+
) on 
PSP latency and amplitude recorded from Drosophila DLM. 
(A): Representative traces obtained from three different flies in which PSP latency 
is calculated as the time (ms) from stimulus application to the peak of PSP (black 
arrows). (B, C): Bar graphs represent the mean ± SEM of PSP latency (ms) and 
amplitude (mV) recorded from flies of the indicated experimental groups. 
*indicates p< 0.05 compared to WT, **indicate p<0.05 compared to treated 
LRRK2; one-way ANOVA, followed by Bonferroni post-hoc test. 
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Effects of Wse on the PSP responses to high frequency 
stimulation of GFS of LRRK2
WD40
 
We then tested flies by recording the “frequency of following” which consisted in 
applying a train of 10 stimuli at different frequencies (100 or 200 Hz) to GFS. As 
previously reported [48], in WT flies, a train of 10 stimulations at 100 Hz induced 
repetitive responses of DLM with minimal decrement of PSP amplitude as 
compared to the first PSP (Fig 4A and 4B).  
The response to 100 Hz stimulation in LRRK2
WD40
 was not different from that 
observed in WT (Fig 4A and 4B). In contrast, the response to 100 Hz in Wse-
treated LRRK2
WD40
 (L
-
/A
+
) flies revealed a significant decrement of PSP amplitude 
when compared to the first PSP (Fig 4A and 4B). At the higher frequency of 
electrical stimulation, the DLM responses of WT started to decrease in amplitude 
after the 2nd PSP with 200 Hz stimulations (Fig 4A and 4C).  
The same protocol of recording at 200 Hz performed in untreated LRRK2
WD40
 flies 
showed that DLM responded to each of the 10 stimulations whose amplitude of 
PSPs was only slightly diminished (Fig 4A and 4C). In treated LRRK2
WD40
 (L
-
/A
+
) 
insects stimulations at 200 Hz elicited DLM PSPs which, similarly to WT flies, 
had amplitudes that decreased with respect to the first PSP. Two-ways ANOVA 
revealed a significant effect of the untreated-LRRK2
WD40 
group compared to WT 
when responding to the 200-Hz stimulation (P<0.05) 
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Figure 4. Effect of LRRK2 gene mutation and treatment with Wse on the 
“frequency of following” recorded in Drosophila DLM. 
(A): Representative traces obtained from three different flies in which PSPs were 
evoked in response to 10 stimulations at 100 (top) or 200 Hz (bottom).             
(B,C): Scatter plot graphs showing the changes in PSP amplitude following 
stimulation at 100 (B) or 200 Hz (C). All values are expressed as the mean ± SEM 
of the % relative to the amplitude of the first PSP. *indicates p< 0.05 compared to 
WT and Wse-untreated LRRK2 (B) and compared to WT and Wse-treated LRRK2 
(C), two-way ANOVA. 
74 
 
Effects of Wse on the subcellular morphology of LRRK2
WD40
 
Fig 5 shows representative transmission electron microscopy images of thoracic 
ganglia and antennal lobes (ALs) of untreated Dm LRRK2 mutants (A) and of 1% 
and 10% Wse-treated, as L
-
/A
+
 (B and C) and as L
+
/A
+
 (D-F), insects. In 
mitochondria of the thoracic ganglia of LRRK2 mutants, we observed regions with 
several damaged, swollen, and with clearly fragmented cristae, that we failed to 
find in the corresponding regions after treatment with 1% Wse (in Fig 5 compare A 
with B and C).  
However, after treatment with 10% Wse L
+
/A
+
, we observed, in the corresponding 
regions of the thoracic ganglia, numerous altered mitochondria with a granular, 
irregularly shaped electron-dense material in their matrix (Fig 5D and 5E). 
Moreover after the same treatment we observed, in Drosophila LRRK2
WD40
ALs 
numerous late endosomes/ phagosomes vacuoles inside presynaptic terminals and 
dendrites (Fig 5F). 
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Figure 5. Samples of transmission electron microscopy images of thoracic ganglia 
and antennal lobes in Drosophila LRRK2 mutant (A) and after treatment with 1% 
in L
-
/A
+
 insects (B, C) and 10% L
+
/A
+
 (D-F) extract of Wse. 
(A): abnormal mitochondria in the thoracic ganglia neuropil of Drosophila 
LRRK2. (B, C): conventional mitochondria in thoracic ganglia of Drosophila 
LRRK2 after treatment with 1% Wse L
-
/A
+
 imaged at low (B) and higher 
magnification (C). (D, E): abnormal mitochondria in Drosophila LRRK2 thoracic 
ganglia cell bodies after treatment with 10% Wse L
+
/A
+
. Note the irregular 
electron-dense substance clearly recognizable inside the mitochondria. (F and 
Inset): numerous endosomes are present inside the antennal lobes neurites of 
Drosophila LRRK2 after treatment with 10% Wse. Scale bars are 0.5 μm except in 
B that is 2.5 μm. 
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Discussion 
One of the aims of the present study was to validate the use of LRRK2
WD40
 as a 
model of PD. In this respect, these mutant flies show reduced lifespan, and motor 
impairments (face validity) and mitochondrial dysfunctions (construct validity) that 
characterize Parkinsonism. Furthermore, this study was aimed at evaluating the 
action of the standardized extract of the roots of Withania somnifera (Wse) and its 
possible neuroprotective effects on the Parkinson’s genetic model of Drosophila 
melanogaster LRRK2
WD40
. Although almost all of the mutations in LRRK2 have a 
number of related features, these mutants object of the present study lack, in 
particular, the WD40 domain responsible for coding a protein chaperone known to 
be involved in a number of cellular functions such as cytoskeletal, neurotransmitter 
vesicular pathway and lyso-endosomal activities [25] The results presented here 
show that the addition of 1% Wse to standard diet of only LRRK2
WD40
 adults (L
-
/A
+
), but not of L
+
/A
+
, significantly a) increases their lifespan compared to 
untreated controls and b) improves their locomotor abilities and c)affects evoked 
electrophysiological parameters. Furthermore, in thoracic ganglia, under electron 
microscopy observation, we found that Wse administration dramatically rescued 
the mutation-related loss of mitochondrial structural integrity. 
Interestingly, Wse chronic administration to flies as L
+
/A
+
, no matter the 
concentration, induces a worsening of symptoms associated with parkinsonism and 
a further decrease of lifespan as compared to WT controls as well as to untreated 
LRRK2
WD40
 (Fig 1B) 
The flight muscle degeneration accompanied by defects in motor activity [50–52] 
detected in our study is probably related to dysfunction of dopaminergic neurons. 
Accordingly, in a zebrafish model LRRK2 loss-of-function in the WD40 domain, it 
was previously reported a rescue of motor impairment following L-Dopa 
administration in the early larval stage from days post fecundation (DPF) 5 to 6 
[49]. Notably, although this and our model of LRRK2 loss-of-function differ in a 
number of factors such as animal species, life period and duration of L-Dopa 
administration, the present results also demonstrate an improvement of motor 
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deficit (climbing activity) in the mutants of the group I treated as L
-
/A
+
. However, 
extension of the treatment to flies of group II and III did not rescue the mutation-
dependent impairment but elicited a worsening in both L
-
/A
+
 and L
+
/A
+
 treated 
flies (Fig 2B). 
The observed rescue of impaired motor ability by Wse administration to 
LRRK2
WD40
 Dm while confirming the condition of mutation-dependent impaired 
motility, as shown in tests of climbing (Fig 2), also supports the suggestion 
that Wse’s effects might be attributable to increased neurotransmission [53][54]that 
would result in a better locomotion. Electrophysiological data showed that 
mutation of the LRRK2 gene was associated with a significant decrease in PSP 
latency when compared to WT animals, an effect that was no longer apparent in 
LRRK2 (L
-
/A
+
) flies that were treated with Wse 1%. However, no significant 
change of PSP peak amplitude was detected among flies from the different 
experimental groups suggesting that in LRRK2
WD40
 mutants there is a higher 
probability of (but not necessarily an optimally coordinated) muscle contraction 
compared with WT without changes in muscle contraction per se. 
Surprisingly, Wse treatment was able to revert the effect of mutation making the 
response latencies recorded in LRRK2 (L
-
/A
+
) treated flies much higher as 
compared with both untreated LRRK2 and WT flies. The decrease in PSP latency 
together with the decreased responsiveness to high frequency stimulation observed 
in untreated-LRRK2
WD40
 flies appears to well correlate with the motility 
impairment observed in these flies. As for the possible mechanism, Augustin and 
colleagues [48] reported that recording the “frequency of following”, a GFS train 
stimulation at 200 Hz induced in WT a significant decrement of PSP amplitude 
relative to the first PSP because the intermediary synapses do not have sufficient 
time to recover between stimuli. Conversely, a stimulation train at 200 Hz 
performed in untreated LRRK2
WD40
 flies showed that, relative to the first PSP, the 
amplitude of PSPs was only slightly diminished, starting from the second response, 
and treatment with 1% Wse made the responses similar to those observed in WT. 
Thus, the effect of Wse on the functional changes associated with the mutation 
clearly discloses a beneficial aspect of this treatment. At this time, we cannot 
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explain in deep details the abnormal effect of Wse treatment in LRRK2 flies (i.e. 
increased PSP latency and exacerbated effect on 100 Hz response vs WT), and this 
might at least in part be justified recalling the complexity of the projection pathway 
from the brain to the thoracic ganglion, where axons form electrical synapses with 
interneurons and the latter form chemical synapses on each motor neuron 
innervating the DLMs [55][56]. However, mutation of LRRK2
WD40
 may be 
correlated with a significant impairment in neurotransmitter release from 
presynaptic terminals [25][57]. 
The impaired motility shown by the LRRK2 mutants is paralleled by the presence 
of scattered abnormal mitochondria in their thoracic ganglia, an observation 
corroborated by other studies that suggest the involvement of LRRK2
WD40
 in 
mitochondrial homeostasis, responsible of mitochondrial degradation[58][59]. 
Intriguingly, the conventional mitochondrial morphology of LRRK2
WD40
 flies 
observed after treatment with 1% Withania extract, and paralleled by an 
improvement in their motor capacity, suggests that Wse may also act suppressing 
mitochondrial dysfunction, as has been recently demonstrated for a green tea-
derived catechin, epigallocatechin gallate (EGCG) [59] and as well as already 
demonstrated in the case of the mutant PINK1
B9
 treated with the standardized 
seeds extract of another plant,Mucuna pruriens [33]. 
In conclusion, based on our results we can infer that the LRRK2 loss-of-function in 
the WD
40
domain is a plausible model that recapitulates some of the essential 
features of Parkinsonism and that the extract of Ws can be usefully employed to 
counteract some deficits associated with this condition.  
However, as demonstrated by Poddighe et al., [33] after Mucuna pruriens 
administration to Dm PINK1
B9
 mutant model of PD, the use of a whole herbal 
extract requires careful assessment.  In fact, the effects of Wse on LRRK2
WD40
  
might also be related to age (group I vsIII), length of exposure (L
-
/A
+
 vs L
+
/A
+
) 
and Wse  (0.1% vs 1% vs 10%) concentrations as suggested by the observation of 
its effects on climbing (Fig 2A and 2C) as well as on life duration (Fig 1C and 1D). 
Indeed, the negative effect of 10% Wse both on WT (Fig 1B) and on the loss-of-
function  LRRK2
WD40 
mutant indicates that one or more components of the extract, 
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when administered chronically and at a concentration higher than optimal, may 
have toxic effects. This conclusion is supported by the observation that chronic 
administration of Wse to flies as L
+
/A
+
, no matter the concentration, and also at 
10%  to L
-
/A
+
, induces a worsening of symptoms associated with parkinsonism and 
a further reduction of lifespan as compared to WT controls and untreated 
LRRK2
WD40
. This observation also indicates that Wse shows a concentration 
threshold, below which it does not work; b) has an optimal value for its effects; but 
c) whose effects at higher concentrations and/or after longer exposures became 
toxic. As discussed above, this suggests that Wse exerts its effects -as a drug- 
following a hormesis-like dose-response curve [60] and further highlights the need 
to assess the proper concentration of Wse. In this regard, the presence of numerous 
large sized lysosomes observed exclusively in the ALs 
of Drosophila LRRK2
WD40
 treated with 10% Wse, corroborates its toxic effect, 
since lysosomes increases in number and size are one of the more common cause 
of degenerative brain disorders [61]. 
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Supporting Information 
 
 
 
Figure S1 Percentages of insects able to achieve the test. 
(A-B): Percentages of adult males WT, LRRK2, Wse 1% treated LRRK2 (A) and 
L-Dopa 0.01% (0.5mM) treated LRRK2 (B), that could climb unto, or above, the 
line drawn at 6 cm from the bottom of the tube within 10 seconds.Treatments were 
administered to flies both only when adults (L
−
/A
+
) and from their larval stage to 
the end of their life-cycle (L
+
/A
+
), and their effects were assayed at three different 
age steps (I: 3–6; II: 10–15; III: 20–25 days) of flies’ life-span. Values are average 
± SEM. * indicates p<0.05 at one-way ANOVA followed by LSD post hoc test as 
compared to WT; ** indicates p<0.05 at one-way ANOVA followed by LSD post 
hoc test as compared to LRRK2. 
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